Skip to main content

Posts

Investigational Product consideration element in a Decentralized Clinical Trial:

BayBiotech.NET I nvestigational Product consideration element in a Decentralized Clinical Trial: In any traditional clinical study, administration of the investigational product (IP) to the study participants should be performed under the supervision of the investigator or the delegate medical representative. If a clinical study is considering a decentralized clinical trial model, there are certain factors to be considered for IP administration. For IP that has a high-risk safety profile, especially in the immediate post administration period, may need on-site dose administration under close supervision of the protocol trained principal investigator. However, for IP with a defined safety and stability profile and with well-understood low risk characterization may be administered at local health care facilities, mobile research facilities or at study participant's home. Regardless, for an investigational product, a well-established chain of custody and well documented accountabilit...
Recent posts
BayBiotech.NET Mobile Health App Interactive Tool If you are developing a mobile health app checkout the interactive tool  to figure out the federal regulatory, privacy and security laws that may apply to your App.  More than regulations might be applicable depending on the scope but this website links all relevant regulations on FTC website. Link:  https://www.ftc.gov/business-guidance/resources/mobile-health-apps-interactive-tool
BayBiotech.NET
BayBiotech.NET International Compilation of Human Research Standards 2024 Edition is shared as a reference document that elaborates the guidelines that protects research participants in over 130 countries globally. This information is compiled by Office for Human Research Protections (OHRP), Office of the Assistant Secretary for Health (OASH) and U.S. Department of Health and Human Services (HHS).  Link: https://www.hhs.gov/sites/default/files/ohrp-international-compilation-human-research-standards-2024.pdf
BayBiotech.NET Swift adoption of DCTs (decentralized clinical trials): a side effect of COVID-19 pandemic https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093545/pdf/main.pdf
BayBiotech.NET Interoperability is path to optimizing digital medicine In order to use big data, artificial intelligence to its full potential, interoperability is the key to success, although the concept compromises data privacy and might lead to challenges. Cures act and Health Interoperability supports evaluation of IT systems and build core capabilities to begin sharing data via APIs (application programming interfaces).